Zobrazeno 1 - 10
of 240
pro vyhledávání: '"G. Seipelt"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Christoph Kahl, Sebastian Stintzing, Werner Scheithauer, Salah-Edin Al-Batran, Christoph Lerchenmüller, Dominik Paul Modest, Andreas Jung, Volker Heinemann, Thomas Kirchner, Ludwig Fischer von Weikersthal, Thomas Decker, Markus Moehler, Lisa Miller-Phillips, Tobias Heintges, G. Seipelt, Alexander Kiani, Frank Kullmann, Swantje Held, Florian Kaiser
Publikováno v:
British Journal of Cancer
Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e1f3c0ca76a04fa9a3cf26d1f70c02
Autor:
Andreas Jung, Markus Moehler, Werner Scheithauer, Tobias Heintges, Jobst C. von Einem, Martina Stauch, Christoph Kahl, Frank Kullmann, Swantje Held, Alexander Kiani, Thomas Kirchner, Salah-Eddin Al-Batran, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Fire study investigators, Sebastian Stintzing, Ursula Vehling-Kaiser, Dominik Paul Modest, Christian A. Lerchenmuller, G. Seipelt
Publikováno v:
International Journal of Cancer. 140:1918-1925
We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773257054f983763ffa9fe57f120c5df
https://doi.org/10.1002/ijc.30592
https://doi.org/10.1002/ijc.30592
Autor:
S-E. Al-Batran, G. Seipelt, Sebastian Stintzing, Dominik Paul Modest, L. Fischer von Weikersthal, Alexander Kiani, Christoph Kahl, Arndt Stahler, J. C. von Einem, Thomas Decker, W. Scheithauer, Volker Heinemann, T. Kirchner, Lisa Miller-Phillips, Andreas Jung, Frank Kullmann, Ursula Vehling-Kaiser
Publikováno v:
Annals of Oncology. 31:S429
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f80b5d94a65a79449458e56f4076d6b8
https://doi.org/10.1016/j.annonc.2020.08.552
https://doi.org/10.1016/j.annonc.2020.08.552
Autor:
Tobias Heintges, Ludwig Fischer von Weikersthal, Andreas Jung, Jobst C. von Einem, Salah-Eddin Al-Batran, Joerg Hielscher, Ursula Vehling-Kaiser, Thomas Decker, Werner Scheithauer, Volker Heinemann, Dominik Paul Modest, Christian A. Lerchenmuller, Alexander Kiani, Michael Scholz, Sebastian Stintzing, G. Seipelt, Christoph Kahl, Thomas Kirchner, Martina Stauch
Publikováno v:
Journal of Clinical Oncology. 38:4070-4070
4070 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) to FOLFIRI plus bevacizumab (bev) as first-line treatment in KRAS WT mCRC patients. FOLFIRI plus c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::427c5d9b2476addcedd59634262ba36b
https://doi.org/10.1200/jco.2020.38.15_suppl.4070
https://doi.org/10.1200/jco.2020.38.15_suppl.4070
Autor:
Dominik Paul Modest, Jobst C. von Einem, Salah-Eddin Al-Batran, Thomas Decker, Swantje Held, Sebastian Stintzing, Alexander Kiani, Markus Moehler, Christoph Kahl, Frank Kullmann, Ludwig Fischer von Weikersthal, G. Seipelt, Werner Scheithauer, Volker Heinemann, Julian Walter Holch, Ursula Vehling-Kaiser, Tobias Heintges
Publikováno v:
Oncotarget
// Dominik Paul Modest 1, 2 , Sebastian Stintzing 1, 2 , Ludwig Fischer von Weikersthal 3 , Thomas Decker 4 , Alexander Kiani 5 , Ursula Vehling-Kaiser 6 , Salah-Eddin Al-Batran 7 , Tobias Heintges 8 , Christoph Kahl 9 , Gernot Seipelt 10 , Frank Kul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb3817e9c6cd5592151a0ff5030350fe
https://pubmed.ncbi.nlm.nih.gov/29285289
https://pubmed.ncbi.nlm.nih.gov/29285289
Autor:
Christoph B. Westphalen, Sebastian Stintzing, Christoph Kahl, L. Fischer von Weikersthal, Dominik Paul Modest, Ursula Vehling-Kaiser, Thomas Decker, Julian Walter Holch, S.-E. Al-Batran, G. Seipelt, Ingrid Ricard, J. C. von Einem, Alexander Kiani, Tobias Heintges, Volker Heinemann, M. Moehler, Swantje Held, Frank Kullmann, Werner Scheithauer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
Background We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in FIRE-3 were investigated in the context of time and exposure to applied treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c026cf263089ec9d6e02a7fc7212edb1
https://pubmed.ncbi.nlm.nih.gov/28942867
https://pubmed.ncbi.nlm.nih.gov/28942867
Autor:
A. Jagenburg, Thomas Kirchner, Lisa Miller-Phillips, S.-E. Al-Batran, Swantje Held, Christoph Kahl, Martina Stauch, Sebastian Stintzing, M. Moehler, Werner Scheithauer, G. Seipelt, Dominik Paul Modest, Thomas Decker, Tobias Heintges, Andreas Jung, Alexander Kiani, L. Fischer von Weikersthal, Volker Heinemann, Ursula Vehling-Kaiser, Frank Kullmann
Publikováno v:
European journal of cancer (Oxford, England : 1990). 79
Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab in patients with RAS-mutant tumours needs to be furth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3566575f099b08842a8c921d2ca54b1
https://pubmed.ncbi.nlm.nih.gov/28463756
https://pubmed.ncbi.nlm.nih.gov/28463756